{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:10:15Z","timestamp":1789013415191,"version":"build-2803163510"},"reference-count":94,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T00:00:00Z","timestamp":1632787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shield Therapeutics (UK) Ltd","award":["00000000"],"award-info":[{"award-number":["00000000"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Iron deficiency is the most common cause of anemia globally and is frequently reported in patients with underlying inflammatory conditions, such as inflammatory bowel disease (IBD) and chronic kidney disease (CKD). Ferric maltol is a new oral iron replacement therapy designed to optimize iron absorption while reducing the gastrointestinal adverse events associated with unabsorbed free iron. Ferric maltol has been studied in clinical trials involving almost 750 adults and adolescents with iron-deficiency anemia associated with IBD, CKD, and other underlying conditions, and it has been widely used in clinical practice. It is approved for the treatment of adults with iron deficiency with or without anemia, independent of the underlying condition, and is commercially available in Europe and the United States. We review the published evidence for ferric maltol, which demonstrates consistent and clinically meaningful improvements in hemoglobin and measures of iron availability (ferritin and transferrin saturation) and shows that it is well-tolerated over long-term treatment for up to 64 weeks\u2014an important consideration in patients with chronic underlying conditions such as IBD and CKD. We believe that ferric maltol is an effective, convenient, and well-tolerated treatment option for iron deficiency and iron-deficiency anemia, especially when long-term management of chronic iron deficiency is required. Writing support was provided by Shield Therapeutics (Gateshead, UK).<\/jats:p>","DOI":"10.3390\/jcm10194448","type":"journal-article","created":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T21:38:09Z","timestamp":1632865089000},"page":"4448","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Iron Replacement Therapy with Oral Ferric Maltol: Review of the Evidence and Expert Opinion"],"prefix":"10.3390","volume":"10","author":[{"given":"Carsten","family":"Schmidt","sequence":"first","affiliation":[{"name":"Medical Clinic II, Department of Gastroenterology, Hepatology, Endocrinology, Diabetology and Infectious Diseases, Klinikum Fulda, Pacelliallee 4, 36043 Fulda, Germany"},{"name":"Medical Faculty, Friedrich Schiller University, 07747 Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6675-249X","authenticated-orcid":false,"given":"Stephen","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Kopyt","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Nephrology, Lehigh Valley Hospital, 1230 S Cedar Crest Boulevard, Suite 301, Allentown, PA 18103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Pergola","sequence":"additional","affiliation":[{"name":"Renal Associates PA, 1123 N Main Av., Suite 120, San Antonio, TX 78212, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2021, September 17). Vitamin and Mineral Nutrition Information System: Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Available online: https:\/\/www.who.int\/vmnis\/indicators\/haemoglobin.pdf."},{"key":"ref_2","unstructured":"National Institute for Health and Care Excellence (2021, September 17). Anaemia\u2014Iron Deficiency. Available online: https:\/\/cks.nice.org.uk\/topics\/anaemia-iron-deficiency\/."},{"key":"ref_3","first-page":"830","article-title":"Global, regional, and national prevalence of anemia and its causes in 204 countries and territories, 1990\u20132019","volume":"4","author":"Gardner","year":"2020","journal-title":"Curr. Dev. Nutr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(15)60865-0","article-title":"Iron deficiency anaemia","volume":"387","author":"Lopez","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Gargallo-Puyuelo, C.J., Alfambra, E., Garc\u00eda-Erce, J.A., and Gomollon, F. (2018). Iron treatment may be difficult in inflammatory diseases: Inflammatory bowel disease as a paradigm. Nutrients, 10.","DOI":"10.3390\/nu10121959"},{"key":"ref_6","first-page":"164","article-title":"Review on iron and its importance for human health","volume":"19","author":"Abbaspour","year":"2014","journal-title":"J. Res. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1159\/000107927","article-title":"Nonhematological benefits of iron","volume":"27","author":"Agarwal","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/gut.2003.035758","article-title":"Iron, anaemia, and inflammatory bowel diseases","volume":"53","author":"Gasche","year":"2004","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4291\/wjgp.v6.i3.62","article-title":"Iron deficiency anemia in inflammatory bowel disease","volume":"6","author":"Kaitha","year":"2015","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1097\/MEG.0000000000000200","article-title":"Anaemia from a patient perspective in inflammatory bowel disease: Results from the European Federation of Crohn\u2019s and Ulcerative Colitis Association\u2019s online survey","volume":"26","author":"Danese","year":"2014","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2015.11.178","article-title":"The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure\u2014Results from the Studies Investigating Co-morbidities Aggravating Heart Failure","volume":"205","author":"Ebner","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Eriksson, D., Goldsmith, D., Teitsson, S., Jackson, J., and van Nooten, F. (2016). Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol., 17.","DOI":"10.1186\/s12882-016-0312-9"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Nielsen, O.H., Soendergaard, C., Vikner, M.E., and Weiss, G. (2018). Rational management of iron-deficiency anaemia in inflammatory bowel disease. Nutrients, 10.","DOI":"10.3390\/nu10010082"},{"key":"ref_14","first-page":"22","article-title":"Prevalence of iron deficiency without anaemia in inflammatory bowel disease and impact on health-related quality of life","volume":"41","year":"2018","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/eurheartj\/ehs224","article-title":"Iron deficiency and heart failure: Diagnostic dilemmas and therapeutic perspectives","volume":"34","author":"Jankowska","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1542\/peds.107.6.1381","article-title":"Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States","volume":"107","author":"Halterman","year":"2001","journal-title":"Pediatrics"},{"key":"ref_17","first-page":"2087","article-title":"Iron deficiency and cognitive functions","volume":"10","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s12325-017-0566-z","article-title":"Real-world impact of cardiovascular disease and anemia on quality of life and productivity in patients with non-dialysis-dependent chronic kidney disease","volume":"34","author":"Covic","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"568S","DOI":"10.1093\/jn\/131.2.568S","article-title":"Iron biology in immune function, muscle metabolism and neuronal functioning","volume":"131","author":"Beard","year":"2001","journal-title":"J. Nutr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1039\/c8mt00146d","article-title":"The human iron-proteome","volume":"10","author":"Andreini","year":"2018","journal-title":"Metallomics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/10408360701428257","article-title":"The regulation of cellular iron metabolism","volume":"44","author":"Chua","year":"2007","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","article-title":"Hepcidin and iron homeostasis","volume":"1823","author":"Ganz","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.bbadis.2015.03.011","article-title":"An overview of molecular basis of iron metabolism regulation and the associated pathologies","volume":"1852","author":"Silva","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ecco-jcc\/jju009","article-title":"European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases","volume":"9","author":"Dignass","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.amjmed.2008.07.012","article-title":"Individualized treatment for iron-deficiency anemia in adults","volume":"121","author":"Alleyne","year":"2008","journal-title":"Am. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Kumar, A., and Brookes, M.J. (2020). Iron therapy in inflammatory bowel disease. Nutrients, 12.","DOI":"10.3390\/nu12113478"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"D\u2019amico, F., Peyrin-Biroulet, L., and Danese, S. (2020). Oral iron for IBD patients: Lessons learned at time of COVID-19 pandemic. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051536"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s12185-017-2373-3","article-title":"Modern iron replacement therapy: Clinical and pathophysiological insights","volume":"107","author":"Girelli","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/ajcn\/69.2.250","article-title":"Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers","volume":"69","author":"Lund","year":"1999","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tolkien, Z., Stecher, L., Mander, A.P., Pereira, D.I., and Powell, J.J. (2015). Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: A systematic review and meta-analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0117383"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1046\/j.1365-2036.2001.01113.x","article-title":"Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis","volume":"15","author":"Carrier","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Yilmaz, B., and Li, H. (2018). Gut microbiota and iron: The crucial actors in health and disease. Pharmaceuticals, 11.","DOI":"10.3390\/ph11040098"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1080\/00313029600169763","article-title":"Iron tablets cause histopathologically distinctive lesions in mucosal biopsies of the stomach and esophagus","volume":"28","author":"Eckstein","year":"1996","journal-title":"Pathology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2559.2008.03081.x","article-title":"Iron-induced mucosal pathology of the upper gastrointestinal tract: A common finding in patients on oral iron therapy","volume":"53","author":"Kaye","year":"2008","journal-title":"Histopathology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/BF01535729","article-title":"Effect of oral iron therapy on the upper gastrointestinal tract. A prospective evaluation","volume":"33","author":"Laine","year":"1988","journal-title":"Dig. Dis. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000496966","article-title":"Safety of oral and intravenous iron","volume":"142","author":"DeLoughery","year":"2019","journal-title":"Acta Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gutjnl-2014-307720","article-title":"Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants","volume":"64","author":"Jaeggi","year":"2015","journal-title":"Gut"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1688s","DOI":"10.3945\/ajcn.117.156067","article-title":"The effects of iron fortification and supplementation on the gut microbiome and diarrhea in infants and children: A review","volume":"106","author":"Paganini","year":"2017","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jnutbio.2019.01.010","article-title":"A decrease in iron availability to human gut microbiome reduces the growth of potentially pathogenic gut bacteria: An in vitro colonic fermentation study","volume":"67","author":"Parmanand","year":"2019","journal-title":"J. Nutr. Biochem."},{"key":"ref_40","unstructured":"World Health Organization (2021, September 17). WHO Model List of Essential Medicines: Ferrous salt. Available online: https:\/\/list.essentialmeds.org\/recommendations\/143."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"f4822","DOI":"10.1136\/bmj.f4822","article-title":"Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials","volume":"347","author":"Litton","year":"2013","journal-title":"BMJ"},{"key":"ref_42","first-page":"Cd007857","article-title":"Parenteral versus oral iron therapy for adults and children with chronic kidney disease","volume":"2","author":"Hodson","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/ckj\/sfv142","article-title":"Safety concerns about intravenous iron therapy in patients with chronic kidney disease","volume":"9","author":"Longhi","year":"2016","journal-title":"Clin. Kidney J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.blre.2015.07.006","article-title":"Iron therapy in chronic kidney disease: Recent changes, benefits and risks","volume":"30","author":"Ribeiro","year":"2016","journal-title":"Blood Rev."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Snook, J., Bhala, N., Beales, I.L.P., Cannings, D., Kightley, C., Logan, R.P., Pritchard, D.M., Sidhu, R., Surgenor, S., and Thomas, W. (2021). British Society of Gastroenterology guidelines for the management of iron deficiency anaemia in adults. Gut, (Epub ahead of print).","DOI":"10.1136\/gutjnl-2021-325210"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ajh.24201","article-title":"How we diagnose and treat iron deficiency anemia","volume":"91","author":"Auerbach","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.drudis.2015.07.005","article-title":"Addressing unmet needs in inflammatory bowel disease","volume":"20","author":"Bokemeyer","year":"2015","journal-title":"Drug Discov. Today"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Kontoghiorghes, G.J., Kolnagou, A., Demetriou, T., Neocleous, M., and Kontoghiorghe, C.N. (2021). New era in the treatment of iron deficiency anaemia using trimaltol iron and other lipophilic iron chelator complexes: Historical perspectives of discovery and future applications. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115546"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.2042-7158.1987.tb06249.x","article-title":"Effects of the pyrones, maltol and ethyl maltol, on iron absorption from the rat small intestine","volume":"39","author":"Barrand","year":"1987","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/0006-2952(88)90556-4","article-title":"Characteristics of iron(III) uptake by isolated fragments of rat small intestine in the presence of the hydroxypyrones, maltol and ethyl maltol","volume":"37","author":"Levey","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/j.2042-7158.1990.tb05408.x","article-title":"The importance of reductive mechanisms for intestinal uptake of iron from ferric maltol and ferric nitrilotriacetic acid (NTA)","volume":"42","author":"Barrand","year":"1990","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.2042-7158.1990.tb05407.x","article-title":"Lipid peroxidation effects of a novel iron compound, ferric maltol. A comparison with ferrous sulphate","volume":"42","author":"Singh","year":"1990","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1476-5381.1991.tb12187.x","article-title":"Evidence for regulatory control of iron uptake from ferric maltol across the small intestine of the rat","volume":"102","author":"Barrand","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1476-5381.1991.tb12240.x","article-title":"Dissociation of a ferric maltol complex and its subsequent metabolism during absorption across the small intestine of the rat","volume":"102","author":"Barrand","year":"1991","journal-title":"Br. J. Pharmacol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2710.1991.tb00292.x","article-title":"Absorption of low and therapeutic doses of ferric maltol, a novel ferric iron compound, in iron deficient subjects using a single dose iron absorption test","volume":"16","author":"Kelsey","year":"1991","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1079\/BJN19940127","article-title":"Absorption of iron from ferric hydroxypyranone complexes","volume":"71","author":"Maxton","year":"1994","journal-title":"Br. J. Nutr."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/000456320003700405","article-title":"Assessment of iron absorption from ferric trimaltol","volume":"37","author":"Reffitt","year":"2000","journal-title":"Ann. Clin. Biochem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.24297\/jac.v12i4.2174","article-title":"Stopped-flow kinetic study of reduction of ferric maltol complex by ascorbate","volume":"12","author":"Amin","year":"2016","journal-title":"J. Adv. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s13318-016-0334-5","article-title":"Randomized open-label phase 1 study of the pharmacokinetics of ferric maltol in inflammatory bowel disease patients with iron deficiency","volume":"42","author":"Bokemeyer","year":"2017","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_60","first-page":"A84","article-title":"PTH-102 Ferric maltol, unlike ferrous sulphate, does not adversely affect the intestinal microbiome","volume":"68","author":"Mahalhal","year":"2019","journal-title":"Gut"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1046\/j.1365-2036.1998.00380.x","article-title":"Ferric trimaltol corrects iron deficiency anaemia in patients intolerant of iron","volume":"12","author":"Harvey","year":"1998","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1097\/MIB.0000000000000314","article-title":"Ferric maltol is effective in correcting iron deficiency anemia in patients with inflammatory bowel disease: Results from a phase-3 clinical trial program","volume":"21","author":"Gasche","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S339","DOI":"10.1093\/ecco-jcc\/jju027.639","article-title":"Correcting iron deficiency anaemia in IBD with oral ferric maltol: Use of proton pump inhibitors does not affect efficacy","volume":"9","author":"Ahmad","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/apt.13665","article-title":"Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: Long-term extension data from a Phase 3 study","volume":"44","author":"Schmidt","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_65","first-page":"A262","article-title":"PTH-113 Disease activity affects response to enteral iron supplementation: Post-hoc analysis of data from the AEGIS study","volume":"66","author":"Quraishi","year":"2017","journal-title":"Gut"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.1016\/j.jval.2018.09.2596","article-title":"PSY19\u2014Using a Bayesian network meta-analysis (NMA) to compare ferric maltol to treatments for iron deficiency and iron deficiency anaemia excluding CHF and CKD patients","volume":"21","author":"Jones","year":"2018","journal-title":"Value Health"},{"key":"ref_67","first-page":"176","article-title":"Effect of oral ferric maltol on iron parameters in patients with chronic kidney disease (CKD) and varying degrees of inflammation: A randomized, controlled trial","volume":"29","author":"Kopyt","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2000616","DOI":"10.1183\/13993003.00616-2020","article-title":"Oral iron supplementation with ferric maltol in patients with pulmonary hypertension","volume":"56","author":"Olsson","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e000530","DOI":"10.1136\/bmjgast-2020-000530","article-title":"Ferric maltol Real-world Effectiveness Study in Hospital practice (FRESH): Clinical characteristics and outcomes of patients with inflammatory bowel disease receiving ferric maltol for iron-deficiency anaemia in the UK","volume":"8","author":"Cummings","year":"2021","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_70","first-page":"A252","article-title":"PTU-124 Real world tolerability & efficacy of oral ferric maltol (Feraccru) in IBD associated anaemia","volume":"67","author":"Oppong","year":"2018","journal-title":"Gut"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Howaldt, S., Dom\u00e8nech, E., Martinez, N., Schmidt, C., and Bokemeyer, B. (2021). Long-term effectiveness of oral ferric maltol versus intravenous ferric carboxymaltose for the treatment of iron-deficiency anemia in patients with inflammatory bowel disease: A randomized controlled noninferiority trial. Inflamm. Bowel Dis., (Epub ahead of print).","DOI":"10.1093\/ibd\/izab073"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Pergola, P.E., and Kopyt, N.P. (2021). Oral ferric maltol for the treatment of iron-deficiency anemia in patients with chronic kidney disease: Phase 3, multicenter, randomized, placebo-controlled trial and open-label extension. Am. J. Kidney Dis., (Epub ahead of print).","DOI":"10.1053\/j.ajkd.2021.03.020"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e090","DOI":"10.1097\/PG9.0000000000000090","article-title":"Safety, tolerability and pharmacokinetics of oral ferric maltol in children with iron deficiency: Phase 1 study","volume":"2","author":"Allen","year":"2021","journal-title":"JPGN Rep."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.jval.2018.09.2669","article-title":"PSY94\u2014Cost-effectiveness model comparing therapeutic strategies for treating iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD)","volume":"21","author":"Tremblay","year":"2018","journal-title":"Value Health"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/j.jval.2018.04.585","article-title":"Comparing short form\u20136 dimension (SF-6D) derived utilities and EuroQol questionnaire\u20145 dimensions (EQ-5D) mapped utilities among patients with iron deficiency in inflammatory bowel disease (ID-IBD) treated with ferric maltol (FM) vs placebo","volume":"21","author":"Tremblay","year":"2018","journal-title":"Value Health"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"S452","DOI":"10.1016\/j.jval.2018.09.2673","article-title":"PSY98\u2014Cost-effectiveness analysis of ferric maltol versus ferric carboxymaltose for the treatment of iron deficiency anaemia in IBD patients in Sweden and Finland","volume":"21","author":"Hjelmgren","year":"2018","journal-title":"Value Health"},{"key":"ref_77","first-page":"1066","article-title":"Evaluation of ferric maltol as alternative to parenteral iron therapy in patients with inflammatory bowel disease (IBD) in terms of costs reductions and healthcare human resource utilisation","volume":"2","author":"Lovato","year":"2018","journal-title":"Hemasphere"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1093\/ecco-jcc\/jjx180.605","article-title":"P478 Treatment with ferric maltol associated with improvements in quality of life for IBD patients with iron deficiency anaemia","volume":"12","author":"Schmidt","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"S319","DOI":"10.1093\/ecco-jcc\/jjz203.460","article-title":"P331 Productivity loss in patients with inflammatory bowel disease receiving treatment for iron deficiency anaemia: A comparison of ferric maltol and IV iron","volume":"14","author":"Howaldt","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"S478","DOI":"10.1093\/ecco-jcc\/jjz203.695","article-title":"P567 Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and inflammatory bowel disease, and relationship with haemoglobin and serum iron","volume":"14","author":"Howaldt","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S558","DOI":"10.1093\/ecco-jcc\/jjz203.813","article-title":"P685 Healthcare resource use associated with ferric maltol and IV iron treatment for iron deficiency anaemia in patients with inflammatory bowel disease","volume":"14","author":"Howaldt","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S541","DOI":"10.1093\/ecco-jcc\/jjab076.713","article-title":"P592 Costs savings associated with ferric maltol and the reduced use of intravenous iron based on real world data","volume":"15","author":"Howaldt","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Mahalhal, A., Frau, A., Burkitt, M.D., Ijaz, U.Z., Lamb, C.A., Mansfield, J.C., Lewis, S., Pritchard, D.M., and Probert, C.S. (2021). Oral ferric maltol does not adversely affect the intestinal microbiome of patients or mice, but ferrous sulphate does. Nutrients, 13.","DOI":"10.3390\/nu13072269"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S424","DOI":"10.1093\/ecco-jcc\/jjab076.544","article-title":"P420 Comparative efficacy and safety of oral ferric maltol in inflammatory bowel disease patients with mild-to-moderate vs. more severe iron deficiency anaemia","volume":"15","author":"Akriche","year":"2021","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000336181","article-title":"Equivalent effects on fecal reactive oxygen species generation with oral supplementation of three iron compounds: Ferrous sulfate, sodium iron EDTA and iron polymaltose","volume":"60","author":"Orozco","year":"2012","journal-title":"Ann. Nutr. Metab."},{"key":"ref_86","first-page":"53","article-title":"Iron supplementation in young iron-deficient females causes gastrointestinal redox imbalance: Protective effect of a fermented nutraceutical","volume":"28","author":"Bertuccelli","year":"2014","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_87","unstructured":"European Medicines Agency (2021, September 17). Feraccru: EPAR\u2014Public Assessment Report. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/feraccru-epar-public-assessment-report_en.pdf."},{"key":"ref_88","unstructured":"European Medicines Agency (2021, September 17). Feraccru (Ferric Maltol) Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/feraccru-epar-product-information_en.pdf."},{"key":"ref_89","unstructured":"Food & Drug Administration (2021, September 17). Accrufer (Ferric Maltol) Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212320Orig1s000lbl.pdf."},{"key":"ref_90","unstructured":"Swissmedic (2021, September 17). Feraccru Product Information. Available online: https:\/\/www.swissmedicinfo.ch\/?Feraccru."},{"key":"ref_91","unstructured":"British Columbia Guidelines and Protocols Advisory Committee (2021, September 17). Iron Deficiency\u2014Diagnosis and Management, Available online: https:\/\/www2.gov.bc.ca\/assets\/gov\/health\/practitioner-pro\/bc-guidelines\/iron-deficiency.pdf."},{"key":"ref_92","unstructured":"ClinicalTrials.gov (2021, September 17). Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04626414."},{"key":"ref_93","first-page":"Cd013529","article-title":"Interventions for treating iron deficiency anaemia in inflammatory bowel disease","volume":"1","author":"Gordon","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e2308","DOI":"10.1097\/MD.0000000000002308","article-title":"Intravenous versus oral iron for the treatment of anemia in inflammatory bowel disease: A systematic review and meta-analysis of randomized controlled trials","volume":"95","author":"Bonovas","year":"2016","journal-title":"Medicine"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/19\/4448\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:06:03Z","timestamp":1760166363000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/19\/4448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":94,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["jcm10194448"],"URL":"https:\/\/doi.org\/10.3390\/jcm10194448","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,28]]}}}